CTOR_OUT_1 [2025-03-31 04:21:47 -0400] 2450 Bytes | 710 tokens | Cum: 710 tkns (8.88% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 4:21:44 AM on Mon Mar 31, 2025 -0400, and I'm firing up the spotlight on Citius Oncology (CTOR), moving from 0.665 to 0.9799. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

Here's the first list of news for Citius Oncology:

C1 - Feb-14-25 04:30PM - Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
C2 - Feb-06-25 08:55AM - Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
C3 - Jan-07-25 08:08AM - Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
C4 - Jan-07-25 08:08AM 07:57AM - Citius Oncology to explore strategic alternatives
C5 - Jan-06-25 07:50AM - Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
C6 - Dec-31-24 07:10AM - Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital
C7 - Dec-27-24 05:00PM - Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
C8 - Dec-27-24 05:00PM 05:00PM - Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Prior AI Reports for CTOR:
1. 2025-03-25 – Score: 55 – Target: 0.9500 – Highs: 0.9800 / 0.9400 / 0.66
citius-oncology-shows-signs-of-rebound-despite-underperformance
2. 2025-03-24 – Score: 35 – Target: 0.8500 – Highs: 0.7214 / 0.9800 / 0.94
citius-oncologys-stock-struggles-amidst-revenue-stagnation-and-high-debt

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Citius Oncology (CTOR)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

CTOR_OUT_3 [2025-03-31 04:21:49 -0400] 1099 Bytes | 295 tokens | Cum: 1007 tkns (12.59% of 8k)
==========================================================================

Showing C1 (chunk 1 of 11): C1:
**Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update**
Date: Feb-14-25 04:30PM
Source: (PR Newswire)
URL: https://www.prnewswire.com/news-releases/citius-oncology-inc-reports-fiscal-first-quarter-2025-financial-results-and-provides-business-update-302377259.html

CRANFORD, N.J.,Feb. 14, 2025/PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq:CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal first quarter endedDecember 31, 2024.

Fiscal First Quarter 2025 Business Highlights and Subsequent Developments

"During the first fiscal quarter of 2025, Citius Oncology advanced key initiatives to bring LYMPHIR to market and focused on exploring strategic options to maximi

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CTOR_OUT_5 [2025-03-31 04:21:50 -0400] 907 Bytes | 264 tokens | Cum: 1273 tkns (15.91% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-26T17:05:38Z - 12 Health Care Stocks Moving In Wednesday's Intraday Session - Acrivon Therapeutics (NASDAQ:ACRV), A...
A2 - 2025-03-24T21:05:45Z - 12 Health Care Stocks Moving In Monday's After-Market Session - Aspira Womens Health (NASDAQ:AWH), C...
A3 - 2025-03-18T12:07:56Z - 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - bioAffinity Technologies (NASDAQ:BIAF...
A4 - 2025-03-17T21:05:46Z - 12 Health Care Stocks Moving In Monday's After-Market Session - BioAtla (NASDAQ:BCAB), Capstone Hold...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CTOR_OUT_7 [2025-03-31 04:21:52 -0400] 1098 Bytes | 344 tokens | Cum: 1619 tkns (20.24% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Wednesday's Intraday Session - Acrivon Therapeutics (NASDAQ:ACRV), Aclarion (NASDAQ:ACON)**Date: 2025-03-26Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44498940/12-health-care-stocks-moving-in-wednesdays-intraday-sessionGainers Petros Pharma PTPI shares rose 246.0% to $0.2 during Wednesday's regular session. The market value of their outstanding shares is at $5.0 million. OSR Holdings OSRH shares increased by 112.49% to $3.4. The market value of their outstanding shares is at $65.5 million. Ocean Biomedical OCEA stock increased by 92.07% to $0.11. The company's market cap stands at $15.3 million. AquaBounty Techs AQB stock increased by 46.09% to $0.99. The market value of their outstanding shares is at $3.8 million. Aspira Womens Health AWH stock increased by 21.36% to $0.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CTOR_OUT_9 [2025-03-31 04:21:53 -0400] 267 Bytes | 67 tokens | Cum: 1688 tkns (21.10% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CTOR_OUT_11 [2025-03-31 04:21:54 -0400] 1004 Bytes | 350 tokens | Cum: 2041 tkns (25.51% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-02-14 10-Q PART I - FIN INFO

Item 1. Fin Stmnts.

CITIUS ONCOLOGY, INC.

COND CONS BAL SHEETS

(Unaudited)

December 31, 2024 September 30, 2024 Curr Assets: Cash and cash equiv $ 112 $ 112 Inventory 14,381,369 8,268,766 Prepaid expen...

S2 - 2025-02-14 10-Q PART I - FIN INFO

Item 1. Fin Stmnts.

CITIUS ONCOLOGY, INC.

COND CONS BAL SHEETS

(Unaudited)

December 31, 2024 September 30, 2024 Curr Assets: Cash and cash equiv $ 112 $ 112 Inventory 14,381,369 8,268,766 Prepaid expen...

S3 - 2025-02-14 10-Q PART I - FIN INFO

Item 1. Fin Stmnts.

CITIUS ONCOLOGY, INC.

COND CONS BAL SHEETS

(Unaudited)

December 31, 2024 September 30, 2024 Curr Assets: Cash and cash equiv $ 112 $ 112 Inventory 14,381,369 8,268,766 Prepaid expen...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CTOR_OUT_13 [2025-03-31 04:22:00 -0400] 1098 Bytes | 373 tokens | Cum: 2416 tkns (30.20% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

CITIUS ONCOLOGY, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

December 31, 2024 September 30, 2024 Current Assets: Cash and cash equivalents $ 112 $ 112 Inventory 14,381,369 8,268,766 Prepaid expenses 2,700,000 2,700,000 Total Current Assets 17,081,481 10,968,878 Other Assets: In-process research and development 73,400,000 73,400,000 Total Other Assets 73,400,000 73,400,000 Total Assets $ 90,481,481 $ 84,368,878 LIABILITIES AND STOCKHOLDERS EQUITY Current Liabilities: Accounts payable $ 5,874,577 $ 3,711,622 License payable 28,400,000 28,400,000 Accrued expenses 6,228,612 Due to related party 2,896,329 588,806 Total Current Liabilities 43,399,518 32,700,428 Deferred tax liability 1,992,240 1,728,000 Note payable to related party 3,800,111 3,800,111 Total Liabilities 49,191,869 38,228,539 Stockholders Eq

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CTOR_OUT_15 [2025-03-31 04:22:08 -0400] 4104 Bytes | 1159 tokens | Cum: 3719 tkns (46.49% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+-----------------------+
| Volume: 205,114 | Perf Month: -44.12% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+-----------------------+
| Avg Volume: 124.47K | Perf Quarter: -29.26% | Short Float: 0.79% | ROE: 3.49% |
+---------------------+-----------------------+------------------------+-----------------------+
| Rel Volume: 1.65 | Index: - | Short Ratio: 0.22 | ROI: -46.26% |
+---------------------+-----------------------+------------------------+-----------------------+
| RSI (14): 37.83 | Market Cap: 47.58M | Short Interest: 0.03M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+-----------------------+
| ATR (14): 0.12 | Shs Outstand: 71.55M | Beta: 0.13 | EPS Surprise: -50.00% |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA20: -14.19% | Shs Float: 3.52M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA50: -36.45% | Inst Own: 0.29% | Sales past 5Y: 0.00% | Earnings: Feb 14 AMC |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA200: -82.62% | Insider Own: 95.08% | Employees: - | |
+---------------------+-----------------------+------------------------+-----------------------+
| Perf Week: 7.26% | Insider Trans: 0.00% | Debt/Eq: 0.09 | |
+---------------------+-----------------------+------------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: {'value': -6659205.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.665
Average Volume: 183101.85
30-Day High: 1.09
30-Day Low: 0.5711

[Detailed Financials: Q1 2025]
- Total Assets: $90,481,481.0
- Total Liabilities: $49,191,869.0
- Total Equity: $41,289,612.0
- Current Assets: $17,081,481.0
- Current Liabilities: $43,399,518.0

[Income Statement: Q1 2025]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.09

[Cash Flow Statement: Q1 2025]
- Net Cash Flow: N/A

[Detailed Financials: FY 2024]
- Total Assets: $84,368,878.0
- Total Liabilities: $38,228,540.0
- Total Equity: $46,140,339.0
- Current Assets: $10,968,878.0
- Current Liabilities: $32,700,429.0

[Income Statement: FY 2024]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.31

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $112
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

CTOR_OUT_17 [2025-03-31 04:22:12 -0400] 676 Bytes | 167 tokens | Cum: 4135 tkns (51.69% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

CTOR_IN_19 [2025-03-31 04:22:12 -0400] 126 Bytes | 29 tokens | Cum: 4236 tkns (52.95% of 8k)
==========================================================================

====================================
[2025-03-31 04:22:12] # Analysis Completed
Elapsed Time: 28.30 seconds